UBS Group
ADXN

UBS Group’s Addex Therapeutics ADXN Stock Holding History

UBS Group’s Portfolio ADXN Stock Details ADXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-156
Closed -$1.2K – 10414
2025
Q4 		$1.2K Buy
156
+155
+15,500% +$1.33K ﹤0.01% 9661
2025
Q3 		$9 Buy
+1
New +$9 ﹤0.01% 10196
2023
Q4 		– Sell
-4
Closed -$28 – 9235
2023
Q3 		$28 Buy
+4
New +$40 ﹤0.01% 9086
2023
Q1 		– Sell
-726
Closed -$9.15K – 9537
2022
Q4 		$9.15K Buy
726
+374
+106% +$5.52K ﹤0.01% 8685
2022
Q3 		$6K Sell
352
-46
-12% -$1.03K ﹤0.01% 8991
2022
Q2 		$9K Buy
398
+258
+184% +$19.4K ﹤0.01% 8109
2022
Q1 		$14K Sell
140
-725
-84% -$79.2K ﹤0.01% 7917
2021
Q4 		$109K Buy
865
+215
+33% +$32.4K ﹤0.01% 6237
2021
Q3 		$117K Buy
650
+14
+2% +$2.7K ﹤0.01% 5718
2021
Q2 		$122K Buy
636
+510
+405% +$104K ﹤0.01% 5724
2021
Q1 		$26K Buy
126
+121
+2,420% +$27.1K ﹤0.01% 7121
2020
Q4 		$1K Sell
5
-52
-91% -$12.9K ﹤0.01% 8190
2020
Q3 		$14K Buy
+57
New +$13.8K ﹤0.01% 6566

Other funds holding ADXN

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group's ADXN Position: Q1 2026 in Review

UBS Group sold out of Addex Therapeutics (ADXN) in Q1 2026, closing a stake of 156 shares — an estimated $1.2K sold.

UBS Group first reported a position in ADXN in Q3 2020 and held it in 13 quarters. The position peaked at $122K in Q2 2021. 4 funds tracked by Wall St. Rank hold ADXN as of Q1 2026.

  • UBS Group reported no remaining Addex Therapeutics position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 156 Addex Therapeutics shares in Q1 2026, an estimated $1.2K.
  • UBS Group first reported a position in Addex Therapeutics in Q3 2020 and held it in 13 quarters.
  • UBS Group's Addex Therapeutics position peaked at $122K in Q2 2021.
  • 4 funds tracked by Wall St. Rank held Addex Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.